BIOCRYST PHARMACEUTICALS, INC. Deferred Revenue
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Deferred Revenue of $0 as of 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2024-02-27
- 2023-12-31: Deferred Revenue, Current $0.00.
- 2023-09-30: Deferred Revenue, Current $522.00K.
- 2023-06-30: Deferred Revenue, Current $1.78M.
- 2023-03-31: Deferred Revenue, Current $1.20M.
| Period end | Deferred Revenue, Current |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-27 |
| 2023-09-30 | $522.00K 10-Q · filed 2023-11-08 |
| 2023-06-30 | $1.78M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $1.20M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $1.22M 10-K · filed 2024-02-27 |
| 2022-09-30 | $1.55M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $1.52M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $1.47M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $1.42M 10-K · filed 2023-02-27 |
| 2021-09-30 | $602.00K 10-Q · filed 2021-11-04 |
| 2021-06-30 | $551.00K 10-Q · filed 2021-08-09 |
| 2021-03-31 | $405.00K 10-Q · filed 2021-05-07 |
| 2020-12-31 | $150.00K 10-K · filed 2022-02-28 |
| 2020-09-30 | $432.00K 10-Q · filed 2020-11-06 |
| 2020-06-30 | $715.00K 10-Q · filed 2020-08-07 |
| 2020-03-31 | $1.07M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $2.12M 10-K · filed 2021-03-01 |
| 2019-09-30 | $221.00K 10-Q · filed 2019-11-08 |
| 2019-06-30 | $221.00K 10-Q · filed 2019-08-08 |
| 2019-03-31 | $221.00K 10-Q · filed 2019-05-09 |
| 2018-12-31 | $221.00K 10-K · filed 2020-03-13 |
| 2018-09-30 | $200.00K 10-Q · filed 2018-11-08 |
| 2018-06-30 | $300.00K 10-Q · filed 2018-08-09 |
| 2018-03-31 | $7.30M 10-Q · filed 2018-05-09 |
| 2018-01-01 | $7.30M 10-K · filed 2019-03-14 |
| 2017-12-31 | $8.48M 10-K · filed 2019-03-14 |
| 2017-09-30 | $8.69M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $1.72M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $1.87M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $2.02M 10-K · filed 2018-03-12 |
| 2016-09-30 | $2.28M 10-Q · filed 2016-11-08 |
| 2016-06-30 | $2.13M 10-Q · filed 2016-08-08 |
| 2015-12-31 | $2.16M 10-K · filed 2017-02-27 |
| 2014-09-30 | $1.48M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $1.48M 10-Q · filed 2014-08-08 |
| 2014-03-31 | $1.47M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $1.47M 10-Q · filed 2014-11-07 |
| 2013-09-30 | $1.54M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $1.54M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $1.54M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $1.39M 10-K · filed 2014-03-10 |
| 2012-09-30 | $1.31M 10-Q · filed 2012-11-08 |
| 2012-06-30 | $4.07M 10-Q · filed 2012-08-08 |
| 2012-03-31 | $2.40M 10-Q · filed 2012-05-08 |
| 2011-12-31 | $9.79M 10-K · filed 2013-03-11 |
| 2011-09-30 | $3.37M 10-Q · filed 2011-11-03 |
| 2011-06-30 | $3.32M 10-Q · filed 2011-08-04 |
| 2010-12-31 | $2.50M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |